Neoadjuvant immunotherapy yielded similar survival and surgical outcomes to upfront surgery in high-risk HCC and could broaden surgical options for traditionally unresectable cases.
led to similar recurrence-free survival and margin-negative resection rates compared with patients undergoing upfront surgery. The study highlights the potential of immunotherapy to expand surgical candidacy in patients with traditionally unresectable HCC .Only about 30% of patients diagnosed with HCC meet the eligibility criteria for surgical resection according to established guidelines.
A total of 92 patients were included in the clinical cohort, with 36 receiving neoadjuvant immune checkpoint inhibitor-based treatment instead of upfront surgery. Of those who received neoadjuvant immunotherapy, the majority were treated with anti–programmed cell death protein 1-based therapy, either as monotherapy , in combination with a tyrosine kinase inhibitor , or in combination with an anti-lymphocyte activation gene 3 protein .
HCC - Hepatocellular Carcinoma Liver Cancer HCC Hepatocellular Cancer Cancer Of The Liver Liver Carcinoma Carcinoma Of The Liver Biologic Therapy Biologics Immunotherapy Neoadjuvant Resection Surgery Hepatic Surgery Liver Surgery Tumor Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Disease Recurrence Liver Tyrosine Kinase Inhibitor Erlotinib
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Is Immunotherapy Best for Unresectable HCC?n the last 10 years, clinical outcomes have improved for patients with unresectable hepatocellular carcinoma (uHCC).
Read more »
How to Manage Unresectable HCC With Liver DysfunctionA recent study published in JAMA Oncology examines the outcomes of uHCC patients with moderate liver dysfunction who are treated with immune checkpoint inhibitor therapy vs best supportive care.
Read more »
FDA Approves Neoadjuvant/Adjuvant Durvalumab for NSCLCThis approval follows recent concerns from an FDA committee that AstraZeneca did not demonstrate that patients needed the immunotherapy both before and after surgery.
Read more »
IASLC Issues Consensus on Neoadjuvant, Adjuvant Treatments in Non–Small Cell Lung CancerMark Kris discusses adjuvant and neoadjuvant therapy consensus guidelines for NSCLC.
Read more »
Endometrial cancer patients see new hope as FDA approves 'transforming' immunotherapy drugThe FDA has approved a new drug for some adult patients with endometrial cancer. Jemperli (dostarlimably) — made by U.K. company GSK — is intended for primary advanced or recurrent disease.
Read more »
Modest Gains Shown in Breast Cancer Immunotherapy TrialsA study found that many breast cancer immunotherapy trials have yielded modest clinical impact, and 25% failed to report outcomes.
Read more »